Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zuranolone,Escitalopram Oxalate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : At the Day 3 primary endpoint, SAGE-217/BIIB125 (Zuranolone), investigational oral neuroactive steroid GABA-A receptor-positive allosteric modulator, 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction i...
Brand Name : SAGE-217
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 16, 2022
Lead Product(s) : Zuranolone,Escitalopram Oxalate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?